Prognostication of Recovery in Early Disorders of Consciousness Study
Launched by UNIVERSITY OF PENNSYLVANIA · Jul 16, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Patients with disorders of consciousness (lacking overt signs of consciousness such as command-following) due to acute brain injury will be identified and enrolled via the Recovery of Consciousness Via Evidence-Based Medicine and Research (RECOVER) Program. Patients in the study will undergo a detailed behavioral consciousness assessment (with the Coma Recovery Scale - Revised \[CRS-R\]), conducted by specially trained personnel, as well as a task-based functional MRI with auditory stimulation (motor commands) to assess for technologic covert consciousness (the willful modulation of brain a...
Gender
ALL
Eligibility criteria
- For patients:
- Inclusion Criteria:
- • Acute brain injury (including, but not limited to ischemic stroke, intracranial hemorrhage, anoxic brain injury, traumatic brain injury, or encephalitis)
- • Inability to follow commands due to a disorder of consciousness (comatose, vegetative, or minimally conscious state) caused by the underlying brain injury
- • Age 18 or greater
- • Enrolled within 28 days of brain injury
- Exclusion Criteria:
- • Imminent death (as indicated, for example, by planned transition to palliative measures, brain death testing, or severe medical instability)
- • MRI contraindications would exclude patients from imaging component of study
- For healthy controls:
- Exclusion Criteria:
- • MRI contraindications
- • History of brain injury to neurological disease
- • History of diabetes, high blood pressure, kidney disease
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
David J Fischer, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported